Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 3/20 | 0.38 |
| ▸ | PGR | P06401 | 16/20 | 0.37 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124453 | 1.00 | ELOVL6 (0.38) | ELOVL6PGRARNR3C1NR3C2 | |
| SCHEMBL4124456 | 1.00 | ELOVL6 (0.38) | ELOVL6PGRARNR3C1NR3C2 | |
| SCHEMBL4126737 | 0.92 | ELOVL6 (0.37) | ELOVL6PGRARNR3C1NR3C2 | |
| SCHEMBL4126731 | 0.92 | ELOVL6 (0.37) | ELOVL6PGRARNR3C1NR3C2 | |
| SCHEMBL4126741 | 0.92 | ELOVL6 (0.37) | ELOVL6PGRARNR3C1NR3C2 | |
| SCHEMBL4113817 | 0.88 | ELOVL6 (0.38) | ELOVL6PGRARNR3C1NR3C2 | |
| SCHEMBL4113810 | 0.88 | ELOVL6 (0.38) | ELOVL6PGRARNR3C1NR3C2 | |
| SCHEMBL4125414 | 0.88 | PGR (0.49) | PGRARNR3C1NR3C2 | |
| SCHEMBL4113818 | 0.88 | ELOVL6 (0.38) | ELOVL6PGRARNR3C1NR3C2 | |
| SCHEMBL4125416 | 0.88 | PGR (0.49) | PGRARNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197878-A1 | SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR | WYETH (US) | 2009-08-06 | — | — | US | claimed |
| US-20090197878-A1 | SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR | WYETH (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197878-A1 | SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR | GNRHR, GPER1, FSHR | ELOVL6 3079/4885PGR 4/4885AR 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.